Phaseline

Companies › GSK

GSK: clinical trials, targets and expected readouts

86 active drug programs in 397 registered trials: 138 Phase 2, 124 Phase 1, 97 Phase 3, 38 Phase 4; Infectious disease, Oncology, Respiratory, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
rMenB+OMV NZ
Meningococcal serogroup B vaccine containing recombinant meningococcal protein and outer m
–Phase 4Meningitis, MeningococcalFeb 2027
Depemokimab
Interleukin-5 inhibitor
IL5Phase 4Nasal Polyps; Eosinophilic Granulomatosis With Polyangiitis; Asthma; Hypereosinophilic Syndrome …Mar 2027
Umeclidinium
Muscarinic acetylcholine receptor M3 antagonist
CHRM3Phase 4Asthma; COPD (Chronic Obstructive Pulmonary Disease); Chronic Obstructive Pulmonary Disease (COPD)Jun 2027
Belimumab
Tumor necrosis factor ligand superfamily member 13B inhibitor
TNFSF13BPhase 4Systemic Lupus Erythematosus; Lung Diseases, Interstitial; Connective Tissue Diseases; Systemic Sclerosis Associated Interstitial Lung Disease …Jun 2027
Varicella Zoster Virus Envelope Glycoprotein E
Envelope glycoprotein E vaccine antigen
–Phase 4Herpes Zoster; RZV Vaccine (Shingrix ®); Varicella Zoster Virus Infection; Autoimmune Rheumatic Diseases …Aug 2027
Mepolizumab
Interleukin-5 inhibitor
IL5Phase 4Asthma; Chronic Rhinosinusitis with Nasal Polyps; Chronic Rhinosinusitis With Nasal Polyps; Nasal Polyps …Jun 2028
Belrestotug
GITR agonist antibody
TNFRSF18Phase 3Lung Cancer, Non-Small Cell; Neoplasms, Head and Neck; NeoplasmsNov 2026
Dostarlimab
Programmed cell death protein 1 antagonist
PDCD1Phase 3Lung Cancer, Non-Small Cell; Neoplasms, Head and Neck; Colonic Neoplasms; Neoplasms, Colon …Nov 2026
Investigational varicella vaccine (VNS Vaccine)
Live attenuated varicella vaccine
–Phase 3ChickenpoxNov 2026
dTpa vaccine (Boostrix)
Inactivated bacterial antigen vaccine against diphtheria, tetanus, and acellular pertussis
–Phase 3Diphtheria-Tetanus-acellular Pertussis VaccinesNov 2026
HFA-152a
hydrofluoroalkane propellant
–Phase 3AsthmaDec 2026
Niraparib
Poly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor
PARP2, PARP1Phase 3Neoplasms, Breast; Ovarian Neoplasms; NeoplasmsDec 2026
Belantamab mafodotin
Tumor necrosis factor receptor superfamily member 17 binding agent; Tubulin inhibitor
TNFRSF17, TubulinPhase 3Multiple Myeloma; Amyloidosis; Plasma Cell Myeloma; Myeloma Multiple …Dec 2026
RSVPreF3 OA investigational vaccine
Respiratory syncytial virus (RSV) vaccine containing RSV fusion (F) protein in prefusion c
–Phase 3Respiratory Syncytial Virus InfectionsDec 2026
Fostemsavir
Envelope polyprotein GP160 inhibitor
INSTI, GP120, CD4Phase 3HIV Infections; HIV-1-infection; Human Immunodeficiency Virus (HIV); HIV Infections With Multi Drug Resistant VirusJan 2027
FF/UMEC/VI
Inhaled corticosteroid/muscarinic antagonist/long-acting beta-2 agonist combination
CHRM3, ADRB2Phase 3AsthmaJan 2027
Candidate varicella vaccine
Live attenuated varicella zoster virus vaccine
–Phase 3ChickenpoxFeb 2027
Cabotegravir
Human immunodeficiency virus type 1 integrase inhibitor
INSTI, INTEGRASEPhase 3HIV Infections; Infection, Human Immunodeficiency Virus; Pre-exposure Prophylaxis; HIV-1 Infected Adults With Controlled Viremia …Mar 2027
Camlipixant (BLU-5937)
P2X purinoceptor 3 antagonist
P2RX3Phase 3Refractory Chronic Cough; Irritable Bowel SyndromeMar 2027
Dolutegravir
Human immunodeficiency virus type 1 integrase inhibitor
INSTI, RTASE, INTEGRASE, RTPhase 3HIV; HIV Infections; HIV-1-infection; Acute HIV Infection …Mar 2027
Lamivudine
Human immunodeficiency virus type 1 reverse transcriptase inhibitor; DNA polymerase/reverse transcriptase inhibitor
RTPhase 3HIV; HIV Infection; HIV Prevention; Pre-exposure Prophylaxis …Mar 2027
GSK5784283 (Felcorekibart)–Phase 3Asthma; Nasal Polyps; Pulmonary Disease, Chronic ObstructiveApr 2027
Tafenoquine (TQ)
8-aminoquinoline antimalarial with activity against hypnozoites
–Phase 3Malaria, VivaxMay 2027
Mocertatug Rezetecan (Mo-Rez)
TROP2-directed antibody-drug conjugate (ADC) with topoisomerase I inhibitor payload
TROP2Phase 3Neoplasms, Endometrial; Ovarian Neoplasms; Tumours, Gynecological; Solid TumorsJun 2027
mRNA Seasonal Flu vaccine
mRNA vaccine encoding influenza antigens
–Phase 3Influenza, HumanJul 2027
Risvutatug Rezetecan (GSK5764227)
anti-B7-H3 antibody-drug conjugate
TROP2, CD276Phase 3Neoplasms, Lung; Neoplasms, Prostate; Neoplasms; Gastrointestinal NeoplasmsAug 2027
Efimosfermin alfa
FGF21 analog
FGF21Phase 3Non-alcoholic Fatty Liver Disease; Metabolic Dysfunction-associated Steatohepatitis; Liver Diseases, AlcoholicOct 2027
IDRX-42 (GSK6042981, velzatinib)
Receptor tyrosine kinase inhibitor
KIT, PDGFRAPhase 3Gastrointestinal Neoplasms; Gastrointestinal Stromal NeoplasmsNov 2027
MMRVNS
Live attenuated vaccine against measles, mumps, rubella, and varicella
–Phase 3MeaslesFeb 2028
Rilpivirine
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
RTPhase 3HIV Infections; Infection, Human Immunodeficiency Virus; HIV-1 Infected Adults With Controlled Viremia; HIV -1 Infection …Jun 2028
CAB ULA
Integrase strand transfer inhibitor (ultra-long-acting formulation)
INSTIPhase 3HIV InfectionsSep 2029
RPV ULA
Non-nucleoside reverse transcriptase inhibitor (ultra-long-acting formulation)
POLR2APhase 3HIV InfectionsSep 2029
Linerixibat
Ileal bile acid transporter inhibitor
SLC10A2Phase 3Cholestasis–
Nelistotug
TIGIT inhibitor
–Phase 2Lung Cancer, Non-Small Cell; Neoplasms, Head and NeckNov 2026
Momelotinib
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Activin receptor type-1 inhibitor
JAK1, JAK2, ACVR1Phase 2Primary Myelofibrosis; Myelodysplastic Syndromes; VEXAS Syndome; Myeloid Leukemia …Dec 2026
GSK3862995B–Phase 2Bronchiectasis; Pulmonary Disease, Chronic ObstructiveDec 2026
Cobolimab
Hepatitis A virus cellular receptor 2 inhibitor
HAVCR2Phase 2Lung Cancer, Non-Small Cell; Melanoma; Neoplasms; Cervical Cancer …Dec 2026
Adjuvanted RSVPreF3 vaccine
RSV PreF3 protein subunit vaccine with adjuvant
RSVPhase 2Respiratory Syncytial Virus InfectionsJan 2027
VH3810109
CD4-targeting monoclonal antibody for HIV latency reversal and viral reservoir reduction
–Phase 2HIV InfectionsJan 2027
MenABCWY vaccine (GSK3536819A)
Combination meningococcal vaccine against serogroups A, B, C, W, and Y
–Phase 2Meningitis, MeningococcalMar 2027
Bepirovirsen
Antisense oligonucleotide targeting hepatitis B virus RNA
HBVPhase 2Hepatitis B; Chronic Hepatitis B Virus InfectionApr 2027
RTS,S/AS01E vaccine
recombinant malaria vaccine targeting circumsporozoite protein
–Phase 2MalariaApr 2027
Daplusiran/Tomligisiran
RNAi therapeutic targeting hepatitis B virus and host factors
HBVPhase 2Chronic Hepatitis B Virus InfectionMay 2027
VH4524184
HIV integrase inhibitor
–Phase 2HIV InfectionsJun 2027
Remzistotug–Phase 2Neoplasms, Head and Neck; NeoplasmsAug 2027
GSK4532990–Phase 2Nonalcoholic Fatty Liver Disease; Liver Diseases, AlcoholicNov 2027
iNTS-TCV
Invasive nontyphoidal Salmonella-typhoid conjugate vaccine
–Phase 2Salmonella InfectionsApr 2028
Efimosfermin (BOS-580)
FGF21 receptor agonist
FGF21RPhase 2Metabolic Dysfunction-Associated SteatohepatitisJul 2028
GSK4527226–Phase 2Alzheimer's DiseaseSep 2028
altSonflex1-2-3
Shigella vaccine
–Phase 2DiarrhoeaOct 2028
Ganfeborole (GSK3036656)–Phase 1Tuberculosis; Pulmonary TuberculosisNov 2026
Pn-MAPS30plus
Pneumococcal polysaccharide vaccine with enhanced immunogenicity formulation
–Phase 1Pneumonia, BacterialNov 2026
Flu/COVm Vaccine
mRNA vaccine encoding seasonal influenza and COVID-19 antigens
–Phase 1Influenza, Human+COVID-19Dec 2026
GSK6097608–Phase 1NeoplasmsDec 2026
Feladilimab
Inducible T-cell costimulator agonist
ICOSPhase 1Multiple MyelomaMar 2027
GSK4528287–Phase 1Colitis, UlcerativeMar 2027
Gsk-3174998 (GSK3174998)
Tumor necrosis factor receptor superfamily member 4 agonist
TNFRSF4Phase 1Multiple MyelomaMar 2027
Isatuximab
Lymphocyte differentiation antigen CD38 inhibitor
CD38Phase 1Multiple Myeloma; Newly Diagnosed Multiple Myeloma; Relapsed Refractory Multiple Myeloma (RRMM); Recurrent Multiple Myeloma …Mar 2027
Nirogacestat
Gamma-secretase inhibitor
APH1A, PSENEN, APH1B, PSEN1, NCSTNPhase 1Multiple Myeloma; Tumor; Desmoid Tumor; AIDS-Related Kaposi SarcomaMar 2027
PED-HZ/su
Recombinant zoster vaccine
–Phase 1Herpes ZosterMar 2027
Albuterol
Beta-2 adrenergic receptor agonist
ADRB2Phase 1Asthma; TTN; LymphangioleiomyomatosisApr 2027
VH4770359
Antiretroviral compound
–Phase 1HIV InfectionsMay 2027
Gepotidacin
Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor
TOPO2APhase 1Urinary Tract InfectionsMay 2027
GSK4771261–Phase 1Kidney DiseaseMay 2027
Candidate UTI vaccine medium dose formulation 1
UTI vaccine
–Phase 1Urinary Tract InfectionsMay 2027
GSK 4-component Strep A Vaccine with Aluminum Hydroxide (Alum)
Streptococcus pyogenes vaccine with aluminum hydroxide adjuvant
–Phase 1Streptococcal InfectionsJun 2027
GSK5458514–Phase 1Neoplasms, ProstateOct 2027
Risvutatug Rezetecan (Ris-Rez)–Phase 1Sarcoma; NeoplasmsNov 2027
Pan-Salmonella-with-Alum vaccine (Low dose)
Quadrivalent Pan-Salmonella vaccine with alum adjuvant
–Phase 1Salmonella InfectionsNov 2027
GSK4527363–Phase 1Systemic Lupus ErythematosusJan 2028
Aletekitug (GSK1070806)
Anti-IL-18 monoclonal antibody
IL18Phase 1Colitis, UlcerativeMar 2028
GSK5926371–Phase 1Systemic Lupus Erythematosus; Lymphoma, Non-HodgkinMar 2028
GSK5471713–Phase 1Neoplasms, ProstateMar 2028
GSK4425689A
monoclonal antibody
–Phase 1Malaria, FalciparumApr 2028
VH4011499–Phase 1HIV InfectionsAug 2028
GSK5460025–Phase 1Neoplasms, ColorectalSep 2028
VH4367310
Cabotegravir prodrug
INSTIPhase 1HIV InfectionsDec 2028
GSK5533524–Phase 1NeoplasmsFeb 2029
RSV/hMPV_V high dose vaccine
RSV and hMPV combination vaccine
–Phase 1Respiratory Syncytial Virus Infections+MetapneumovirusApr 2029
RSV/hMPV_V low dose vaccine
RSV and hMPV combination vaccine
–Phase 1Respiratory Syncytial Virus Infections+MetapneumovirusApr 2029
RSV/hMPV_V medium dose vaccine
RSV and hMPV combination vaccine
–Phase 1Respiratory Syncytial Virus Infections+MetapneumovirusApr 2029
RSV/hMPV_W low dose vaccine
RSV and hMPV combination vaccine
–Phase 1Respiratory Syncytial Virus Infections+MetapneumovirusApr 2029
Ivonescimab
PD-L2 inhibitor
PDCD1LG2Phase 1Neoplasms, LungJun 2029
GSK4418959–Phase 1Neoplasms, Colorectal–
GSK4524101–Phase 1Neoplasms–
VH4527079
Human monoclonal antibody
–Phase 1HIV Infections–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02362503FostemsavirPhase 3HIV InfectionsInfectious diseaseAug 2016
NCT03164564CabotegravirPhase 3HIV InfectionsInfectious diseaseNov 2020
NCT03164564CabotegravirPhase 3HIV InfectionsInfectious diseaseNov 2020
NCT04651777FF/UMEC/VIPhase 3AsthmaRespiratoryAug 2023
NCT04915755NiraparibPhase 3Neoplasms, BreastOncologyJun 2024
NCT05598814MepolizumabPhase 4Chronic Rhinosinusitis with Nasal PolypsRespiratoryAug 2024
NCT04802356Belantamab mafodotinPhase 2Multiple MyelomaOncologyMar 2025
NCT05575830Varicella Zoster Virus Envelope Glycoprotein EPhase 4RZV Vaccine (Shingrix ®)VaccinesApr 2025
NCT05122767DolutegravirPhase 1TuberculosisInfectious diseaseJul 2025
NCT06970223CabotegravirPhase 1HIV InfectionsInfectious diseaseJul 2025
NCT06519357LamivudinePhase 2Mild Cognitive ImpairmentNeurologySep 2025
NCT05870761DostarlimabPhase 2Recurrent Endometrial Serous AdenocarcinomaOncologySep 2025
NCT04337450DolutegravirPhase 2HIV InfectionsInfectious diseaseSep 2025
NCT05527704AlbuterolPhase 3TTNRespiratoryNov 2025
NCT07006246LamivudinePhase 4HIV InfectionInfectious diseaseNov 2025
NCT05583344GSK4532990Phase 2Nonalcoholic Fatty Liver DiseaseGastroenterologyJan 2026
NCT05220358FostemsavirPhase 4HIV-1-infectionInfectious diseaseFeb 2026
NCT07168356BepirovirsenPhase 1Hepatitis BGenitourinaryMar 2026
NCT05626777MepolizumabPhase 4AsthmaRespiratoryMar 2026
NCT05942222MepolizumabPhase 4Chronic Rhinosinusitis With Nasal PolypsRespiratoryApr 2026
NCT06250504CabotegravirPhase 3HIV InfectionsInfectious diseaseApr 2026
NCT03104842IsatuximabPhase 2Multiple MyelomaOncologyMay 2026
NCT06710847GSK4418959Phase 1Neoplasms, ColorectalOncologyJun 2026
NCT06077877NiraparibPhase 1NeoplasmsOncologyJun 2026
NCT06077877GSK4524101Phase 1NeoplasmsOncologyJun 2026
NCT06485154LamivudinePhase 4HIV PreventionInfectious diseaseJun 2026
NCT07636928VH4524184Phase 1HIV InfectionsInfectious diseaseAug 2026
NCT06652958VH4527079Phase 1HIV InfectionsInfectious diseaseSep 2026
NCT05263934DepemokimabPhase 3Eosinophilic Granulomatosis With PolyangiitisImmunologySep 2026
NCT06534892RSVPreF3 OA investigational vaccinePhase 3Respiratory Syncytial Virus InfectionsInfectious diseaseSep 2026
NCT04167358LinerixibatPhase 3CholestasisGastroenterologySep 2026
NCT06521567CobolimabPhase 1MelanomaOncologyOct 2026
NCT06521567DostarlimabPhase 1MelanomaOncologyOct 2026
NCT05565378DostarlimabPhase 2Lung Cancer, Non-Small CellOncologyNov 2026
NCT05565378BelrestotugPhase 2Lung Cancer, Non-Small CellOncologyNov 2026
NCT05565378NelistotugPhase 2Lung Cancer, Non-Small CellOncologyNov 2026
NCT05338190BelimumabPhase 3Primary Immune Thrombocytopenia (ITP)HematologyNov 2026
NCT05526989DostarlimabPhase 2Penile CarcinomaOncologyNov 2026
NCT06517017IsatuximabPhase 2Multiple MyelomaOncologyNov 2026
NCT07784894Ganfeborole (GSK3036656)Phase 1TuberculosisInfectious diseaseNov 2026
NCT07428759Pn-MAPS30plusPhase 1Pneumonia, BacterialInfectious diseaseNov 2026
NCT06567782DostarlimabPhase 2Neoplasms, ColonOncologyNov 2026
NCT07596199dTpa vaccine (Boostrix)Phase 3Diphtheria-Tetanus-acellular Pertussis VaccinesVaccinesNov 2026
NCT06693895Investigational varicella vaccine (VNS Vaccine)Phase 3ChickenpoxInfectious diseaseNov 2026
NCT04165772DostarlimabPhase 2Rectal AdenocarcinomaOncologyNov 2026
NCT04892654DolutegravirPhase 3HIV-1-infectionInfectious diseaseNov 2026
NCT07133880UmeclidiniumPhase 4COPD (Chronic Obstructive Pulmonary Disease)RespiratoryDec 2026
NCT06238635CobolimabPhase 2Cervical CancerOncologyDec 2026
NCT06238635DostarlimabPhase 2Cervical CancerOncologyDec 2026
NCT06832865IsatuximabPhase 2Relapsed Refractory Multiple Myeloma (RRMM)OncologyDec 2026
NCT07464314Flu/COVm VaccinePhase 1Influenza, Human+COVID-19Infectious diseaseDec 2026
NCT03441113MomelotinibPhase 2Primary MyelofibrosisOncologyDec 2026
NCT06317311DostarlimabPhase 2CarcinomaOncologyDec 2026
NCT06806137Investigational varicella vaccine (VNS Vaccine)Phase 3ChickenpoxInfectious diseaseDec 2026
NCT06158126CabotegravirPhase 4Pre-exposure ProphylaxisInfectious diseaseDec 2026
NCT05002816Belantamab mafodotinPhase 1Multiple MyelomaOncologyDec 2026
NCT04403139Varicella Zoster Virus Envelope Glycoprotein EPhase 4Varicella Zoster Virus InfectionInfectious diseaseDec 2026
NCT03016338DostarlimabPhase 2Endometrial CancerOncologyDec 2026
NCT04068753DostarlimabPhase 2Recurrent Cervix CancerOncologyDec 2026
NCT06967753DolutegravirPhase 4HIVInfectious diseaseDec 2026

The 60 nearest readouts of 397 trials; the rest in the app.

From the company's SEC filings

Cash of 3.4bn GBP on 2025-12-31; operating cash flow positive

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

INSTI (5) RT (3) INTEGRASE (2) TROP2 (2) IL5 (2) HBV (2) CHRM3 (2) ADRB2 (2) TNFRSF17 (1) Tubulin (1) TNFRSF4 (1) ICOS (1)

Companies with the same targets

Gilead Sciences Merck & Co. (MSD) Sichuan Baili Pharmaceutical Astellas Beijing Biotech Akeso MacroGenics OBI Pharma Mabwell (Shanghai) Bioscience Bio-Thera Solutions

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.